TSX:VMD

Stock Analysis Report

Viemed Healthcare

Executive Summary

Viemed Healthcare, Inc., through its subsidiaries, provides in-home health care solutions in the United States.

Snowflake

Fundamentals

Solid track record with high growth potential.

Share Price & News

How has Viemed Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.7%

VMD

0.5%

CA Healthcare

-0.3%

CA Market


1 Year Return

32.0%

VMD

-15.4%

CA Healthcare

0.9%

CA Market

Return vs Industry: VMD exceeded the Canadian Healthcare industry which returned -15.4% over the past year.

Return vs Market: VMD exceeded the Canadian Market which returned 0.9% over the past year.


Share holder returns

VMDIndustryMarket
7 Day4.7%0.5%-0.3%
30 Day12.5%-0.7%-2.1%
90 Day5.7%-9.8%-1.5%
1 Year32.0%32.0%-13.1%-15.4%4.4%0.9%
3 Yearn/a0.4%-13.6%15.7%5.4%
5 Yearn/a61.3%20.7%26.1%7.9%

Price Volatility Vs. Market

How volatile is Viemed Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Viemed Healthcare undervalued based on future cash flows and its price relative to the stock market?

22%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: VMD (CA$10.15) is trading below our estimate of fair value (CA$13.08)

Significantly Undervalued: VMD is trading below fair value, but not by a significant amount.


Price Based on Earnings

PE vs Industry: VMD is good value based on its PE Ratio (31x) compared to the Healthcare industry average (48.5x).

PE vs Market: VMD is poor value based on its PE Ratio (31x) compared to the Canadian market (13.7x).


Price Based on Expected Growth

Low PEG Ratio: VMD is good value based on its PEG Ratio (0.7x)


Price Based on Value of Assets

PB vs Industry: VMD is overvalued based on its PB Ratio (7.4x) compared to the CA Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Viemed Healthcare expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

44.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: VMD's forecast earnings growth (44.3% per year) is above the savings rate (1.9%).

Earnings vs Market: VMD's earnings (44.3% per year) are forecast to grow faster than the Canadian market (13.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VMD's revenue (25.2% per year) is forecast to grow faster than the Canadian market (5.7% per year).

High Growth Revenue: VMD's revenue (25.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if VMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Viemed Healthcare performed over the past 5 years?

3.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VMD's earnings have grown by 3.1% per year over the past 5 years.

Accelerating Growth: VMD's earnings growth over the past year (8.6%) exceeds its 5-year average (3.1% per year).

Earnings vs Industry: VMD earnings growth over the past year (8.6%) exceeded the Healthcare industry -46%.


Return on Equity

High ROE: VMD's Return on Equity (24%) is considered high.


Return on Assets

ROA vs Industry: VMD has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: VMD's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Viemed Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: VMD's short term assets ($25.1M) exceeds its short term liabilities ($24.1M)

Long Term Liabilities: VMD's short term assets (25.1M) exceeds its long term liabilities (7.5M)


Debt to Equity History and Analysis

Debt Level: VMD's debt to equity ratio (12.6%) is considered satisfactory

Reducing Debt: Insufficient data to determine if VMD's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: VMD's debt is well covered by operating cash flow (391.6%).

Interest Coverage: VMD's interest payments on its debt are well covered by EBIT (93x coverage).


Balance Sheet

Inventory Level: VMD has a high level of physical assets or inventory.

Debt Coverage by Assets: VMD's debt is covered by short term assets (assets are 5.077180x debt).


Next Steps

Dividend

What is Viemed Healthcare's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate VMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VMD's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Viemed Healthcare's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Casey Hoyt (42yo)

1.8yrs

Tenure

US$1,828,844

Compensation

Mr. Casey Hoyt has been Director of Viemed Healthcare, Inc. since December 14, 2016 and serves as Chief Executive Officer. Mr. Hoyt served as Chief Executive Officer of Patient Home Monitoring Corp. from  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Casey's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Casey's compensation has increased by more than 20% in the past year.


Management Age and Tenure

1.8yrs

Average Tenure

44yo

Average Age

Experienced Management: VMD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

1.8yrs

Average Tenure

53yo

Average Age

Experienced Board: VMD's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$178,45909 Jan 19
Casey Hoyt
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares32,625
Max PriceUS$5.47
SellUS$173,99009 Jan 19
Michael Moore
EntityIndividual
Role
President
President
Shares31,808
Max PriceUS$5.47
SellUS$68,23809 Jan 19
Trae Fitzgerald
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares12,475
Max PriceUS$5.47
SellUS$243,96709 Jan 19
W. Zehnder
EntityIndividual
Role
Member of the Board of Directors
COO & Director
Shares44,601
Max PriceUS$5.47
BuyUS$66,15520 Nov 18
Michael Moore
EntityIndividual
Role
President
President
Shares11,000
Max PriceUS$6.01
BuyUS$45,43420 Nov 18
Casey Hoyt
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares10,000
Max PriceUS$4.54

Ownership Breakdown


Management Team

  • Robbie Grossman (45yo)

    Corporate Secretary

    • Tenure: 1.8yrs
  • Casey Hoyt (42yo)

    CEO & Director

    • Tenure: 1.8yrs
    • Compensation: US$1.83m
  • Michael Moore (41yo)

    President

    • Tenure: 1.8yrs
    • Compensation: US$1.70m
  • Brett Stoute

    Chief Compliance Officer

    • Tenure: 0yrs
  • W. Zehnder (44yo)

    COO & Director

    • Tenure: 1.8yrs
    • Compensation: US$1.66m
  • William Frazier (61yo)

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
    • Compensation: US$421.34k
  • Trae Fitzgerald (31yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
    • Compensation: US$593.33k
  • Kavish Shah

    Chief Information Officer

    • Tenure: 0yrs
  • Jerome Cambre (48yo)

    Vice President of Sales

    • Tenure: 1.6yrs

Board Members

  • Randy Dobbs (68yo)

    Independent Chairman

    • Tenure: 1.8yrs
    • Compensation: US$213.08k
  • Nitin Kaushal (53yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$213.08k
  • Casey Hoyt (42yo)

    CEO & Director

    • Tenure: 1.8yrs
    • Compensation: US$1.83m
  • W. Zehnder (44yo)

    COO & Director

    • Tenure: 1.8yrs
    • Compensation: US$1.66m
  • William Frazier (61yo)

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
    • Compensation: US$421.34k
  • Tim Smokoff (54yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$213.08k
  • Bruce Greenstein (51yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$112.50k

Company Information

Viemed Healthcare, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viemed Healthcare, Inc.
  • Ticker: VMD
  • Exchange: TSX
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: CA$383.018m
  • Shares outstanding: 37.74m
  • Website: https://www.viemed.com

Number of Employees


Location

  • Viemed Healthcare, Inc.
  • 202 North Luke Street
  • Lafayette
  • Louisiana
  • 70506
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VMDTSX (The Toronto Stock Exchange)YesCommon SharesCACADDec 2017
VMDNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDDec 2017
VIJDB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2017

Biography

Viemed Healthcare, Inc., through its subsidiaries, provides in-home health care solutions in the United States. The company offers respiratory services and related equipment, including non-invasive ventila ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:24
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)